ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "lupus nephritis and systemic lupus erythematosus (SLE)"

  • Abstract Number: 606 • 2013 ACR/ARHP Annual Meeting

    Characteristics Of Lupus Nephritis:  Data From a Large Multicenter Registry Of Patients With Systemic Lupus Erythematosus

    Diane L. Kamen1, Graciela S. Alarcon2, Jill P. Buyon3, Mary Anne Dooley4, Richard A. Furie5, David S. Pisetsky6 and Tammy O. Utset7, 1Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, 2Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 3Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY, 4University of North Carolina at Chapel Hill, Chapel Hill, NC, 5The Feinstein Institute for Medical Research and North Shore-Long Island Jewish Health System, Lake Success, NY, 6Department of Medicine, Duke University Medical Center, Durham, NC, 7Rheumatology, University of Chicago Medical Center, Chicago, IL

    Background/Purpose: Renal disease is strongly associated with morbidity and mortality among SLE patients. We utilized the Lupus Clinical Trials Consortium, Inc. longitudinal registry of SLE…
  • Abstract Number: 2892 • 2013 ACR/ARHP Annual Meeting

    Masp-1/3 Deficient MRL/Lpr Mice Lack The Alternative Complement Pathway Activation and Are Protected From Development Of Lupus-Like Glomerulonephritis

    Takeshi Machida1, Natsumi Sakamoto1, Teizo Fujita1, Minoru Takahashi2 and Hideharu Sekine1, 1Immunology, Fukushima Medical University School of Medicine, Fukushima, Japan, 2Department of Immunology, Fukushima Medical University School of Medicine, Fukushima, Japan

    Background/Purpose: Complement has both protective and pathogenic functions in lupus due to a balance between its role in the clearance of immune complexes (ICs) and…
  • Abstract Number: 1071 • 2013 ACR/ARHP Annual Meeting

    Prevalence Of Systemic Lupus Erythematosus and Lupus Nephritis In The United States: Analysis Of Commercial and Public Insurance Billing Data

    Kunal Gandhi1, Evo Alemao1, Hugh Kawabata1 and Jan L. Hillson2, 1Bristol-Myers Squibb, Princeton, NJ, 2Bristol-Myers Squibb, Seattle, WA

    Background/Purpose:  Prevalence estimates of Systemic Lupus Erythematosus (SLE) in the U.S. vary, with numbers ranging from 161,000 (Helmick, 2008) to 1.5 million (Lupus Foundation of…
  • Abstract Number: 884 • 2013 ACR/ARHP Annual Meeting

    Treatment Of Lupus Nephritis With Abatacept Plus Low-Dose Pulse Cyclophosphamide Followed By Azathioprine (the Euro-Lupus Regimen): Twenty-Four Week Data From a Double-Blind Controlled Trial

    David Wofsy1, Anca Askanase2, Patricia C. Cagnoli3, W. Winn Chatham4, Gabriel Contreras5, Maria Dall'era6, Mary Anne Dooley7, Hilda Fragoso-Loyo8, David R. Karp9, Meenakshi Jolly10, Kenneth Kalunian11, Diane L. Kamen12, Iris Lee13, Marc C. Levesque14, S. Sam Lim15, Meggan Mackay16, Cesar Ramos-Remus17, Brad H. Rovin18, Tammy O. Utset19, Swamy Venuturupalli20, Robert Winchester21, Linna Ding22, Wendy Gao22, Lynette Keyes-Elstein23 and Patti Tosta24, 1Rheumatology/Immunology, University of California San Francisco and NIAID Autoimmunity Centers of Excellence, San Francisco, CA, 2NYU School of Medicine, New York, NY, 3Int Med/Div of Rheum, University of Michigan Health, Ann Arbor, MI, 4University of Alabama at Birmingham, Birmingham, AL, 5University of Miami, Miami, FL, 6Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, 7University of North Carolina at Chapel Hill, Chapel Hill, NC, 8Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico, 9Rheumatic Diseases Division, UT Southwestern Medical Center, Dallas, TX, 10Rheumatology, Rush University Medical Center, Chicago, IL, 11UCSD School of Medicine, La Jolla, CA, 12Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, 13Nephrology, Temple University, Philadelphia, PA, 14Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 15Emory University School of Medicine, Division of Rheumatology, Atlanta, GA, 16Autoimmune & Musculoskeletal Disease, Feinstein Institute for Medical Research, Manhasset, NY, 17Unidad de Investigacion en Enfermedades Cronico-Degenerativas, Guadalajara, Mexico, 18Division of Nephrology, Ohio State University Medical Center, Columbus, OH, 19Rheumatology, University of Chicago Medical Center, Chicago, IL, 20Cedars-Sinai Medical Center, West Hollywood, CA, 21Dept of Medicine & Pathology, Columbia University, New York, NY, 22NIAID, Bethesda, MD, 23Rho Federal Systems, Inc., Chapel Hill, NC, 24Immune Tolerance Network, San Francisco, CA

    Background/Purpose: Studies in murine models for SLE have shown that CTLA4Ig can ameliorate murine lupus nephritis.  Moreover, the combination of CTLA4Ig plus intravenous cyclophosphamide (IVC)…
  • Abstract Number: 2500 • 2012 ACR/ARHP Annual Meeting

    Podocyte Injury in Membranous and Proliferative Lupus Nephritis: Distinct Underlying Mechanisms?

    Gabriela M. Rezende1, Vilma S. T. Viana1, Denise M. Malheiros2, Elaine P. Leon3, Eduardo F. Borba1, Neila AS Silva2, Irene L. Noronha4, Cleonice Silva4 and Eloisa Bonfá5, 1Internal Medicine, Division of Rheumatology - Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 2Division of AnatomoPathology - Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 3Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 4Internal Medicine, Division of Nephrology - Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 5Division of Rheumatology, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil

    Background/Purpose: Lupus nephritis (LN) is a major cause of morbidity and mortality in patients with systemic lupus erythematosus (SLE) with proteinuria being the predominant common…
  • Abstract Number: 2242 • 2012 ACR/ARHP Annual Meeting

    Clinical Manifestations and Predictive Factors for Response to Induction Therapy and Maintenance of Remission in ISN/RPS Class V Lupus Nephritis

    Masanori Hanaoka, Takahisa Gono, Yasushi Kawaguchi, Hirotaka Kaneko, Kae Takagi, Hisae Ichida, Yasuhiro Katsumata, Yuko Okamoto, Yuko Ota, Sayuri Kataoka and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan

    Background/Purpose: The pathophysiology and the content of treatment differ between International Society of Nephrology/Renal Pathology Society (ISN/RPS) class III/IV lupus nephritis (LN) and class V…
  • Abstract Number: 1442 • 2012 ACR/ARHP Annual Meeting

    IRF-1 Deficient Lupus-Prone MRL/Lpr Mice Show Reduced Glomerulonephritis but Develop Severe Interstitial Nephritis, Renal Vasculitis and Pulmonary Granulomas with Propensity for Th2 Polarity

    Hidemaru Sekine1, Takeshi Machida1, Natsumi Sakamoto1, Eiji Suzuki2, Xian Zhang3, Christopher Reilly4 and Gary S. Gilkeson5, 1Immunology, Fukushima Medical University School of Medicine, Fukushima, Japan, 2Medicine, Medical University of South Carolina, Charleston, SC, 3Medicine, Medical University of South Carolina and Ralph H. Johnson VA Medical Center, Charleston, SC, 4Virginia Tech, Blacksburg, VA, 5Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC

    Background/Purpose: The transcription factor interferon regulatory factor-4 (IRF-4) and -1 (IRF-1) are members of the IRF family of transcription regulators and involved in the development…
  • Abstract Number: 1055 • 2012 ACR/ARHP Annual Meeting

    Sec61 Is Indispensable for Antigen Cross-Presentation and the Development of Lupus Nephritis: A Novel ‘Self-Organized Criticality Theory’ Explaining the Cause of Systemic Lupus Erythematosus (SLE)

    Ken Tsumiyama and Shunichi Shiozawa, Department of Medicine, Kyushu University Beppu Hospital, Beppu, Japan

    Background/Purpose:  We found that systemic lupus erythematosus (SLE) was induced experimentally by repeatedly immunizing the mice normally not prone to autoimmune diseases by any exogenous…
  • Abstract Number: 885 • 2012 ACR/ARHP Annual Meeting

    Interferon α and Self-Organized Criticality Theory

    Shunichi Shiozawa1, Yumi Miyazaki2 and Ken Tsumiyama3, 1Department of Medicine, Kyushu University Beppu Hospital, Beppu, Japan, 2Kyushu University Beppu Hospital/ Kobe University Graduate School of Health Sciences, Beppu/ Kobe, Japan, 3Department of Rheumatology, Kyushu University Beppu Hospital, Beppu, Japan

    Background/Purpose: One of the biggest obstacle we face in elucidating the pathogenesis of autoimmunity today is the mechanism how autoreactive lymphocyte clones could survive or…
  • Abstract Number: 838 • 2012 ACR/ARHP Annual Meeting

    Association of Urinary and Serum Soluble Fn14 Levels and TWEAK Levels with Lupus Nephritis Disease Activity

    Irene Blanco1, Ping Wu2, Timothy S. Zheng3, Shawn Weng4, Jennifer S. Michaelson2, Linda C. Burkly2 and Chaim Putterman5, 1Rheumatology, Albert Einstein College of Medicine, Bronx, NY, 2Biogen Idec, Cambridge, MA, 3R&D - Rheumatology/Immunology, Biogen Idec Inc, Cambridge, MA, 4Biogen Idec, Inc., Cambridge, MA, 5Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY

    Background/Purpose: We have showed that the cytokine TWEAK is a biomarker for lupus nephritis (LN). However, soluble receptors for key immune pathways are also potential…
  • Abstract Number: 839 • 2012 ACR/ARHP Annual Meeting

    Urinary Levels of High Mobility Group Box 1 Protein Are Elevated in Patients with Active Lupus Nephritis, and Correlate with Renal Histopathology

    Irene Blanco1, Neelakshi Jog2, Chaim Putterman3, Iris Lee4 and Roberto Caricchio5, 1Rheumatology, Albert Einstein College of Medicine, Bronx, NY, 2Rheumatology, Temple University, Philadelphia, PA, 3Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, 4Nephrology, Temple University, Philadelphia, PA, 5Medicine/Rheumatology, Temple University, Philadelphia, PA

    Background/Purpose: High mobility group box 1 protein (HMGB-1) had been implicated in the pathogenesis of SLE and potentially lupus nephritis (LN).  There is increased expression…
  • Abstract Number: 840 • 2012 ACR/ARHP Annual Meeting

    Do Serum Hepcidin 25 Levels Predict SLE Renal or Non-Renal Flares?

    Alexandra Friedman1, Nicholas Young2, Paul Jensen3, Xiaolin Zhang4, Wael N. Jarjour5, Brad H. Rovin4, Daniel Birmingham3, Lee Hebert3 and Stacy P. Ardoin6, 1Immunology and Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, 2Immunology and Rheumatology, The Ohio State University Medical Center, Columbus, OH, 3Medicine, Ohio State University Medical Center, Columbus, OH, 4Division of Nephrology, Ohio State University Medical Center, Columbus, OH, 5Dept of Rheumatology/Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, 6Pediatric & Adult Rheumatology, Ohio State University College of Medicine, Columbus, OH

    Background/Purpose: Biomarkers are needed which can accurately predict systemic lupus erythematosus (SLE) flare, allowing tailoring of immunosuppressive therapy to minimize disease damage and medication toxicity.…
  • Abstract Number: 661 • 2012 ACR/ARHP Annual Meeting

    Co-Localization of C-Reactive Protein, Immunoglobulin G and Complement in Renal Subendothelial Immune Deposits of Proliferative Lupus Nephritis Detected Using Immunogold Electron Microscopy

    Christopher Sjöwall1, Anders I. Olin2, Thomas Skogh3, Jonas Wetterö4, Mattias Mörgelin2, Ola Nived5, Gunnar Sturfelt6 and Anders A. Bengtsson7, 1Deparment of clinical and experimental medicine, Linkoping University, Linkoping, Sweden, 2Infection Medicine, Department of Clinical Sciences, Lund University, Lund, Sweden, Lund, Sweden, 3Deparment of clinical and experimental medicine, Linköping University, Linköping, Sweden, 4Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden, 5Department of Rheumatology, University Hospital Lund, Lund, Sweden, 6Department of Clinical Sciences Lund, Section of Rheumatology, Lund University, Lund, Sweden, 7Department of Clinical Sciences, Section of Rheumatology, Lund University, Lund, Sweden

    Background/Purpose: The pattern recognition molecules C-reactive protein (CRP) and complement protein 1q (C1q) are pivotal parts of the innate immune system and display relevant biological…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology